According to CNN, on November 16 local time, preliminary data released by American biotechnology company Moderna showed that the effective efficiency of the new crown vaccine developed by the company is 94.5%.
U.S. media data map
Modner Chief Medical Officer said: "It is absolutely surprising to be able to develop this vaccine and see that it can prevent symptomatic diseases so efficiently."
According to reports, a total of 30,000 people participated in the clinical trial of the Moderna vaccine, of which 15,000 participants were injected with normal saline as the control group. Over a few months, 90 people in the control group were infected with the new coronavirus, and 11 of them developed severe illness. Of the other 15,000 vaccinated participants, only 5 were infected with the new coronavirus, and no one developed severe illness.
US media data map
Modner said that the vaccine has no serious side effects, and only a small number of participants have developed temporary symptoms such as physical pain and headache. Moderna plans to apply for a vaccine authorization from the U.S. Food and Drug Administration (FDA) later this month after accumulating more safety data.
US media data map
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that this result is "very exciting" and the effectiveness is 94.5%. This data is very outstanding. He expects that vaccination will begin in late December, with high-risk groups first considering high-risk groups, including medical workers, the elderly and people with underlying diseases. Other populations will be able to start vaccination around April next year, and the process will likely last for several months.
(Editor: YZM)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-